Program
andecaliximab
Also written as “Andecaliximab”, “GS-5745” and “GS-5745 SC”.
Its studies are mostly in Colitis, Ulcerative · Arthritis, Rheumatoid · Myositis Ossificans · Ossification, Heterotopic · Pulmonary Disease, Chronic Obstructive, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gilead Sciences | 120 open or running | phase 3since Aug 7, 2015 | Feb 27, 2013 | none ahead |
| Ashibio | 22 open or running | phase 3since Jun 17, 2024 | Jun 17, 2024 | Dec 2028phase 2 · NCT07024407 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 27, 2013First study: phase 1 study in Pancreatic NeoplasmsNew to Gilead SciencesGilead Sciences · NCT01803282 · 236 enrolled · United States
- Apr 8, 2013Phase 1 study in Colitis, UlcerativeGilead Sciences · NCT01831427 · 74 enrolled · United States, Belgium, Canada and more
- Feb 28, 2014Phase 1 study in Pulmonary Disease, Chronic ObstructiveGilead Sciences · NCT02077465 · 11 enrolled · United States
- Jun 25, 2014Phase 1 study in Arthritis, RheumatoidGilead Sciences · NCT02176876 · 18 enrolled · Czech Republic, Hungary
- Aug 4, 2014Phase 1 study in Colitis, UlcerativeGilead Sciences · NCT02209987 · 28 enrolled · New Zealand
- Mar 27, 2015Phase 2 study in Crohn DiseaseGilead Sciences · NCT02405442 · 187 enrolled · United States, Australia, Canada and more
- Aug 7, 2015Phase 3 study in Colitis, UlcerativeGilead Sciences · NCT02520284 · 165 enrolled · United States, Australia, Belgium and more
- Sep 8, 2015Phase 3 study in Stomach NeoplasmsGilead Sciences · NCT02545504 · 432 enrolled · United States, Australia, Belgium and more
- Apr 29, 2016Phase 2 study in Cystic FibrosisGilead Sciences · NCT02759562 · 6 enrolled · Australia, France, Germany and more
- Aug 8, 20162 phase 2 studiesGilead Sciences · NCT02862574, NCT02864381
- Aug 8, 2016Phase 1 study in Gastric AdenocarcinomaGilead Sciences · NCT02862535 · 36 enrolled · Japan
- Jun 17, 2024Ashibio's first study: phase 3 study in Myositis OssificansNew to AshibioAshibio · NCT06508021 · 92 enrolled · United States
- May 20, 2025Phase 2 study in Ossification, HeterotopicAshibio · NCT07024407 · 10 enrolled · United States
Ahead
- Dec 2028Primary completion: phase 2 study in Ossification, HeterotopicAshibio · NCT07024407
- Feb 4, 2029Primary completion: phase 3 study in Myositis OssificansAshibio · NCT06508021
TargetBeta
“A humanized monoclonal antibody against matrix metalloproteinase 9 (MMP-9), ”NCIt, by rule
“Matrix metalloproteinase 9 inhibitor”ChEMBL 37, by rule
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07024407Ossification, Heterotopic · United States | 2 | Active, not recruiting | Ashibio | Dec 2028 | 10 |
| NCT06508021Myositis Ossificans · United States | 3 | Active, not recruiting | Ashibio | Feb 4, 2029 | 92 |
| NCT02864381Gastric Adenocarcinoma · United States, Australia, Belgium and more | 2 | Completed | Gilead Sciences | Nov 8, 2017 | 144 |
| NCT02862574Arthritis, Rheumatoid · United States | 2 | Terminated | Gilead Sciences | Jun 26, 2017 | 15 |
| NCT02862535Gastric Adenocarcinoma · Japan | 1 | Terminated | Gilead Sciences | Oct 25, 2019 | 36 |
| NCT02759562Cystic Fibrosis · Australia, France, Germany and more | 2 | Terminated | Gilead Sciences | Jul 6, 2017 | 6 |
| NCT02545504Stomach Neoplasms · United States, Australia, Belgium and more | 3 | Completed | Gilead Sciences | May 15, 2019 | 432 |
| NCT02520284Colitis, Ulcerative · United States, Australia, Belgium and more | 3 | Terminated | Gilead Sciences | Sep 2016 | 165 |
| NCT02405442Crohn Disease · United States, Australia, Canada and more | 2 | Terminated | Gilead Sciences | Nov 30, 2016 | 187 |
| NCT02209987Colitis, Ulcerative · New Zealand | 1 | Completed | Gilead Sciences | Oct 2014 | 28 |
| NCT02176876Arthritis, Rheumatoid · Czech Republic, Hungary | 1 | Completed | Gilead Sciences | Apr 2015 | 18 |
| NCT02077465Pulmonary Disease, Chronic Obstructive · United States | 1 | Completed | Gilead Sciences | Oct 27, 2014 | 11 |
| NCT01831427Colitis, Ulcerative · United States, Belgium, Canada and more | 1 | Completed | Gilead Sciences | Jan 5, 2015 | 74 |
| NCT01803282Pancreatic Neoplasms · United States | 1 | Completed | Gilead Sciences | Apr 23, 2019 | 236 |
How it is read
Names in the registry
- “Andecaliximab”, 13 entries
- “GS-5745”, 1 entry
- “GS-5745 SC”, 1 entry
- “GS-5745 IV”, 1 entry
Conditions, from the studies’ own filings
- Colitis, Ulcerative, 3 studies
- Arthritis, Rheumatoid, 2 studies
- Myositis Ossificans, 1 study
- Ossification, Heterotopic, 1 study
- Pulmonary Disease, Chronic Obstructive, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.